Navigation Links
The Lancet publishes new data demonstrating superior efficacy of Victoza(R) (liraglutide [rDNA] injection) compared to Januvia(R) (sitagliptin) in the treatment of type 2 diabetes
Date:4/23/2010

PRINCETON, N.J., April 23 /PRNewswire-FirstCall/ -- Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia®.  The 26-week trial showed that Victoza® produced significantly greater reductions in A1C, fasting plasma glucose (FPG), and body weight than Januvia®, with similar or better overall treatment satisfaction.

In addition, significantly more patients achieved the A1C targets of <7.0% (American Diabetes Association [ADA]).  Nearly twice as many study participants on Victoza® reached the ADA goal compared to the Januvia® group (56% and 44% in the 1.8mg and 1.2mg Victoza® groups versus 22% in the Januvia® group).

"These data clearly show that Victoza® at both doses was more effective than Januvia® at achieving blood sugar control in people with type 2 diabetes with the benefit of weight loss," said Dr. Richard Pratley, of the Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington.  "With so many patients still struggling to lower their blood sugar, Victoza® represents an effective new option."

About the study

The study was a 26-week, randomized, parallel-group, open-label trial comparing safety and efficacy of the two recommended doses of once-daily Victoza® (1.2mg and 1.8mg) with once-daily Januvia® (100mg), all added to metformin.  It was conducted in Europe and North America in 665 people with type 2 diabetes who we
'/>"/>

SOURCE Novo Nordisk
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda(R)) Combination Therapy Reduces Early Breast Cancer Recurrence
2. Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations
3. Landmark Study for GSKs Cervical Cancer Vaccine Published in The Lancet
4. The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
5. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
6. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
9. TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 The leading ... $13 billion global cardiac rhythm management device market ... found that Medtronic, St. Jude Medical, Boston Scientific ... of this market segment. The healthcare market research ... , uses 2015 as a base year, providing ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
(Date:5/22/2015)... , May 22, 2015 Research and ... the addition of the "Latest Regulations on ... report to their offering. This is ... issued a guidance on international multi-center clinical trials ... which has begun to be implemented on March ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 42015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
... -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... from its ZFP Therapeutic program to develop SB-509, a ... endothelial growth factor (VEGF)-A gene as a treatment for ... drug was well-tolerated in subjects with ALS and that ...
... 17, 2010 The Amgen Foundation and Ashoka,s Changemakers today ... Empowerment competition and launched public online voting in search ... voices, and improve health outcomes. The ten ... from 277 entries received from 40 countries. Online ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 2Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 3Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 4Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 5Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 6Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting 7Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 2Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 3Amgen Foundation and Ashoka's Changemakers Announce Finalists in Patients | Choices | Empowerment Competition 4
(Date:5/25/2015)... 25, 2015 Burke Rehabilitation Hospital ... Architects in New York City, to speak at Burke on ... hospital’s ongoing Legacy Lobby Lecture series, will take place at ... is the great grandson of Stanford White of McKim, Mead ... of Burke’s campus 100 years ago. , “We are thrilled ...
(Date:5/24/2015)... Kong (PRWEB) May 25, 2015 Pacific Prime has ... three part report looking at the cost of individual international ... Destinations, Article 2 looks at the cost of health insurance in ... , Focusing on, Hong Kong , ... the UAE , the UK ...
(Date:5/24/2015)... May 24, 2015 Women's Excellence ... hair loss. Although it is unclear about the etiology ... environmental factors such as metabolism, nutritional deficiencies, thyroid abnormalities ... offer a comprehensive approach to evaluating the metabolic, nutritional ... they can help patients find a cause for their ...
(Date:5/24/2015)... May 24, 2015 Women’s Excellence ... take pressure measurements in patients’ bladder and urethra. This ... orders it if they have reported symptoms of stress ... , Women’s Excellence in Bladder Control is a comprehensive ... leakage or problems with overall control of their bladder. ...
(Date:5/24/2015)... EnviroLeather™ by LDI, a leader ... a classic, rugged leather grain with enhanced stain ... including ink, to be easily removed. The collection ... corporate, healthcare, hospitality and education environments. , InkGard ... of developing products that are more sustainable, less ...
Breaking Medicine News(10 mins):Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2
... the official congress of the European Association of Echocardiography ... Cardiology, where techniques of non-invasive diagnostic imaging will be ... at this year,s Congress, with the latest evidence highlighting ... with such rapid development in imaging techniques, it is ...
... National ... away 10,000 free business card pens. , ... (PRWEB) December 2, 2009 -- National Pen ( www.pens.com ), a worldwide leading ... , , , ,“We have a new way to promote business that no other company ...
... ... away from users will be available in early 2010 from Aerius International Ltd. ... (PRWEB) December ... users will be available in early 2010 from Aerius International Ltd. The technology was ...
... ... 900 runners and walkers from Las Vegas and around the country will ... Marathon powered by Zappos.com, raising over $3.2 million for the Crohn,s & ... the official charity of the race, the funds will go toward research, ...
... , CHICAGO, Dec. 2 The American Health Information ... Dowling, PhD, will be the next chief executive of ... Dowling,s extensive health information experience includes academia, systems management, ... He is scheduled to take office January 13, ...
... , WASHINGTON, Dec. 2 ... their campaign against the U.S. House bill,s pro-life Stupak-Pitts Amendment. ... Yoest released this statement in response to the abortion lobby,s ... abortion with health care, the feminist groups and the abortion ...
Cached Medicine News:Health News:Media alert: EUROECHO 2009 2Health News:National Pen Giving Away 10,000 Business Card Pens 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Raising Millions for Team Challenge through Rock &#8216;n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2Health News:Raising Millions for Team Challenge through Rock &#8216;n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3Health News:Raising Millions for Team Challenge through Rock &#8216;n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2
... sources which are implanted in tissue for ... the prostate. The seeds remain in the ... effect, i.e. after radioactive decay is completed. ... They are supplied in a sterile form. ...
... used in Theraseed devices. It is ... grain of rice, are implanted and ... three months it has given up ... lost almost all of it by ...
Non-sterile oncoseed seeds consists of a welded titanium capsule containing....
Four 62 mirrors give a 360 view of the anterior chamber angle with only a slight lens rotation. Posterior pole can be viewed through center of lens....
Medicine Products: